Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8(+) T cells

BACKGROUND: Development of interleukin (IL)-2-dependent antitumor responses focus on targeting the intermediate affinity IL-2R to stimulate memory-phenotypic CD8(+) T and natural killer (NK) cells while minimizing regulatory T cell (Treg) expansion. However, this approach may not effectively engage...

Descripción completa

Detalles Bibliográficos
Autores principales: LaPorte, Kathryn M, Hernandez, Rosmely, Santos Savio, Alicia, Malek, Thomas R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255137/
https://www.ncbi.nlm.nih.gov/pubmed/37270181
http://dx.doi.org/10.1136/jitc-2022-006611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255137/
https://www.ncbi.nlm.nih.gov/pubmed/37270181
http://dx.doi.org/10.1136/jitc-2022-006611

Ejemplares similares